Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | MPO | P05164 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | APAF1 | O14727 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367542 | 1.00 | KDM4E (0.69) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL8244909 | 1.00 | KDM4E (0.69) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL22357157 | 1.00 | KDM4E (0.69) | KDM4EMAPTKMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL6589062 | 0.99 | KDM4E (0.68) | KDM4EMAPTKMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL6587256 | 0.99 | KDM4E (0.68) | KDM4EMAPTKMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL27360830 | 0.99 | KDM4E (0.68) | KDM4EMAPTKMT2AMEN1LMNA | |
| Tryptophan SCHEMBL8591699 | 0.92 | KDM4E (0.80) | KDM4EMAPTKMT2AMEN1LMNA | |
| D-Tryptophan SCHEMBL8588293 | 0.92 | KDM4E (0.80) | KDM4EMAPTKMT2AMEN1LMNA | |
| SCHEMBL5203420 | 0.88 | KDM4E (0.65) | KDM4EMAPTKMT2AMEN1LMNA | |
| Tryptophan Methyl Ester SCHEMBL8588881 | 0.87 | MEN1 (0.60) | KDM4EMAPTKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720087-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246269-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | ZEALAND PHARMA A/S (DK) | 2024-12-05 | — | — | WO | disclosed |
| EP-4471049-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR | Zealand Pharma A/S (DK) | 2024-12-04 | — | — | EP | disclosed |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20200392197-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800826-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190071483-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2019-03-07 | — | — | US | disclosed |
| CN-104284891-B | Conformationally constrained, fully synthetic macrocyclic compounds | 波利弗尔股份公司 | 2018-04-17 | — | — | CN | disclosed |
| WO-2017062334-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2017-04-13 | — | — | WO | disclosed |
| US-8071552-B2 | Peptides and peptidomimetics binding to CD23 | UNIVERSITE BORDEAUX 2 (FR) | 2011-12-06 | — | — | US | disclosed |
| EP-1733231-B1 | PEPTIDES AND PEPTIDOMIMETICS BINDING TO CD23 | UNIV BORDEAUX 2 (FR) | 2011-05-04 | — | — | EP | disclosed |
| US-20080039402-A1 | Peptides and Peptidomimetics Binding to Cd23 | UNIVERSITE BORDEAUX 2 | 2008-02-14 | — | — | US | disclosed |
| EP-1733231-A2 | PEPTIDES AND PEPTIDOMIMETICS BINDING TO CD23 | Université Bordeaux 2 (FR) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005098435-A2 | PEPTIDES AND PEPTIDOMIMETICS BINDING TO CD23 | UNIVERSITE BORDEAUX 2 (FR) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071483-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | GLP1R, GCG, GCGR | KDM4E 1345/4885MAPT 3706/4885KMT2A 1913/4885 |
| US-11773150-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | KDM4E 1345/4885MAPT 3706/4885KMT2A 1913/4885 |
| US-20200392197-A1 | ANTIBODY PEPTIDE CONJUGATES THAT HAVE AGONIST ACTIVITY AT BOTH THE GLUCAGON AND GLUCAGON-LIKE PEPTIDE 1 RECEPTORS | GLP1R, GCG, GCGR | KDM4E 1345/4885MAPT 3706/4885KMT2A 1913/4885 |
| US-10800826-B2 | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors | GLP1R, GCG, GCGR | KDM4E 1345/4885MAPT 3706/4885KMT2A 1913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.